Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to assess antitumor activity of the combination of bevacizumab, pemetrexed and carboplatin, in terms of time to progression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Armando Santoro, MD
• Treatments: Bevacizumab; Carboplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Histologically proven malignant pleural mesothelioma, inoperable, non previously treated with chemotherapy including intracavitary administration

• PS 0-1

• Measurable and/or evaluable lesions according to RECIST criteria

• Adequate organ function

Exclusion Criteria:

• Uncontrolled hypertension

• Evidence of bleeding diathesis or coagulopathy

• Pregnancy or breast-feeding